Homepage
The COPD PLUS Registry is a non-interventional, multicentre, observational, prospective database designed to collect data on patients receiving biological therapy and builds on the original CHOPN Registry.
The project is part of the international INTERFACE project.
Project Objectives
Chronic obstructive pulmonary disease (COPD) is a serious, progressive and incurable disease characterised by irreversible airflow obstruction and the gradual destruction of lung tissue. Smoking is the most common cause, but genetic predisposition, long-term exposure to harmful substances and recurrent respiratory infections also play significant roles.
COPD is among the leading causes of morbidity and mortality worldwide and places a substantial burden on healthcare systems while significantly affecting patients' quality of life.
Standard treatment primarily includes inhaled bronchodilators (LABA, LAMA), inhaled corticosteroids, pulmonary rehabilitation and oxygen therapy. Nevertheless, some patients continue to experience recurrent acute exacerbations, progressive lung damage and inadequate symptom control despite maximal inhaled therapy.
For these patients, biological therapy represents a potential treatment option. Biological agents target specific inflammatory mechanisms involved in the development and progression of COPD.
In a subgroup of patients with eosinophilic inflammation (type 2 inflammation), increased activity of the interleukins IL-4 and IL-13 has been demonstrated, contributing to more frequent exacerbations and a more rapid decline in lung function. Blocking these inflammatory pathways with biological agents can reduce the frequency of exacerbations, improve lung function and consequently enhance patients' quality of life.
Current recommendations (GOLD Strategy 2026) include two therapeutic molecules targeting type 2 (T2) inflammation:
- dupilumab
- mepolizumab
Establishment of the CHOPN PLUS Registry
Establishing the registry is a complex process aimed at creating a unified, methodologically sound platform for the systematic collection of clinical data. The initial phase involves establishing an organisational structure that clearly defines the roles and responsibilities of individual team members.
This is followed by defining the registry's objectives and methodology, including its scientific and clinical aims and the eligibility criteria for patient enrolment.
Equally important are the ethical and legal considerations, including ethics committee approval, preparation of patient informed consent forms, recruitment of participating centres, and the establishment of rules for data sharing and publication.